<DOC>
	<DOC>NCT01439776</DOC>
	<brief_summary>Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 77% of naïve patients with genotype 1-3 Studies rarely address the issues of improving host factors. The current study examines whether adding vitamin D with Peg/RBV, a potent immunomodulator, could improve viral response(SVR)compared to Peg/RBV.</brief_summary>
	<brief_title>Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients</brief_title>
	<detailed_description>The working hypothesis is that Adding vitamin D to conventional Peg/RBV therapy for naïve, genotype 1-3 patients with chronic HCV infection significantly improves RVR, EVR additionally.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Chronic genotype 13 HCV infection Treatment Naive Child B and C HCC patients Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>chronic hepatitis C</keyword>
	<keyword>SVR</keyword>
	<keyword>Vit D</keyword>
	<keyword>Peginterferon alfa 2a</keyword>
	<keyword>Ribavirin</keyword>
</DOC>